Sanofi is reported to be preparing a move to take control of US biotech Ocular Therapeutix, after an initial bid was rejected last year. That is according to French newspaper La Lettre, which said ...

Pune: A team of doctors at a city eye hospital successfully performed complex corneo-scleral tear suturing (a surgical ...

There are a variety of ways that I would like to see new technology used in wet AMD in the future.

BEDFORD, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today ...

Ocular Therapeutix’s lead asset is Axpaxli, being developed for wet age-related macular degeneration. A Phase III study is underway, with data expected this quarter. Rumors of a potential takeover by ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

As you explore the world of Fallout 76, you will need to gather junk to help you build your camp, craft weapons and armor, and generally survive in the wasteland. While some materials are very ...

Although ocular disease commonly occurs in people with rosacea, ocular rosacea remains underrecognized by dermatologists and even eye specialists, according to experts. Fortunately, an ophthalmologist ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Ocular Therapeutix ( (OCUL)) just ...

Ocular Therapeutix’s value hinges on Axpaxli’s Phase 3 success in Wet AMD, with recent protocol changes signaling management’s confidence and bullish prospects. The company is well-capitalized through ...